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Atherosclerosis, the underlying pathology of most cardiovascular diseases, is triggered 
by the retention of apolipoprotein B (apoB)-containing lipoproteins in the arterial wall 
through electrostatic interactions with glycosaminoglycan (GAG) side chains of proteo-
glycans. Previously, we reported the antiatherogenic properties of the chimeric mono-
clonal antibody (mAb) chP3R99-LALA, which binds sulfated GAGs, inhibits low-density 
lipoprotein (LDL)–chondroitin sulfate (CS) association, and abrogates LDL oxidation and 
foam cell formation. In preventive and therapeutic settings, apoE-deficient (apoE−/−) mice 
immunized with 50 μg of this mAb showed reduced atherosclerotic lesions related with 
the induction of autologous anti-GAG antibodies. Knowing that age and sex are major 
non-modifiable risk factors in the development of atherosclerosis, the present study 
aimed to assess the influence of these variables on the capacity of chP3R99-LALA mAb 
to generate an anti-CS antibody response. Also, we aimed at defining the impact of 
the dose of chP3R99-LALA on the anti-CS antibody induction and the atheroprotective 
effect of this mAb in apoE−/− mice. Neither age nor sex had an impact in the IgG anti-CS 
antibody response induced by s.c. immunization with this mAb. Moreover, chP3R99-
LALA mAb reduced atherosclerotic lesions to a similar extent in both young male and 
female apoE−/− mice fed a hypercholesterolemic diet and, in middle-aged female apoE−/− 
mice, with spontaneous lesions. On the other hand, increasing the dose of chP3R99-
LALA (200 vs. 50 μg) elicited an anti-idiotype antibody cascade characterized by higher 
levels of anti-idiotype (Ab2), anti-anti-idiotype (Ab3), and anti-CS antibody responses. 
Moreover, this dose increment resulted in a striking reduction of aortic atherosclerotic 
lesions in immunized mice.
Keywords: atherosclerosis, glycosaminoglycans, monoclonal antibody, idiotypic cascade, atheroprotection, 
antibodies
inTrODUcTiOn
Cardiovascular diseases (CVDs) still prevail as the leading cause of death worldwide (1). 
Furthermore, it was estimated that, by 2025, more than five million men and nearly three mil-
lion women might die prematurely due to CVD (2). Atherosclerosis, the underlying pathology 
in most CVD, is initiated by the subendothelial retention of apoB-containing lipoproteins (3–5). 
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This retention occurs by electrostatic interactions between 
glycosaminoglycan (GAG) chains and basic residues present in 
apoB-containing lipoproteins (6, 7). The trapped lipoproteins 
undergo oxidative and enzymatic modifications that trigger a 
maladaptive, non-resolving inflammatory process (7–13). In 
humans, epidemiological studies have demonstrated that differ-
ent risk factors, including hypercholesterolemia, hypertension, 
diabetes, smoking, age, and gender influence the development 
and progression of atherosclerosis (14–17). Paralleling, what 
happens in humans, apoE-deficient (apoE−/−) mice, one of the 
most widely used murine model of atherosclerosis (18), exhibit 
accelerated atherosclerosis progression when fed a high-fat 
high-cholesterol (HFHC) diet (19, 20). Also, aging increases 
atherosclerosis in both male and female mice, although the influ-
ence of gender in the extent of the disease remains controversial 
(21–24).
Previously, we characterized the antiatherogenic properties 
of the chimeric murine/human monoclonal antibody (mAb) 
chP3R99 and its variant with impaired Fcγ receptor and com-
plement binding (chP3R99-LALA), which bind sulfated GAGs, 
inhibit low-density lipoprotein (LDL)–chondroitin sulfate (CS) 
interaction, abrogate LDL oxidation in  vitro and in  vivo and, 
preferentially, accumulate in arterial lesions (25, 26). In preven-
tive and therapeutic settings, male young adult New Zealand 
White rabbits and apoE−/− mice immunized with this mAb 
showed reduced atherosclerotic lesions, associated with the 
induction of autologous anti-GAG antibodies generated due to 
the activation of an anti-idiotype antibody cascade (Ab2, Ab3, 
etc.) (25–27).
In an effort to expand our previous knowledge on the capacity 
of this mAb to activate such idiotypic network in apoE−/− mice, 
now we evaluated (i) the influence of age and gender in the 
induction of autologous anti-CS antibodies by chP3R99-LALA 
immunization, (ii) the effect of different doses of the mAb 
in the induction of the anti-idiotype antibody cascade, and 
(iii) the effect of the increase of chP3R99-LALA mAb dose in 
aortic atherosclerosis lesions of apoE−/− mice fed a HFHC diet.
MaTerials anD MeThODs
Monoclonal antibodies and reagents
chP3R99-LALA (25), hR3 (28), and ch1E10 (29) IgG1 mAb were 
generated at the Center of Molecular Immunology (Havana, 
Cuba). ch1E10 is an anti-idiotype mAb that specifically reacts 
with chP3R99-LALA mAb variable regions. hR3 is an anti-
human epidermal growth factor receptor antibody used as 
isotype-matched control antibody. The mAbs were purified 
from culture supernatants by protein-A affinity chromatography 
(Pharmacia, Uppsala, Sweden) and analyzed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under 
reducing conditions. The specificity of the purified antibodies was 
confirmed by enzyme-linked immunoadsorbent assay (ELISA) 
and protein concentration was estimated by optical density (OD) 
at 280 nm. CS from bovine trachea was obtained from Sigma-
Aldrich (St. Louis, MO, USA).
animals
Male and female apoE−/− mice were housed under standard con-
ditions (25°C, 60 ± 10% humidity) and exposed to 12 h light/dark 
cycle, with food and water ad libitum. The studies were approved 
by the Institutional Animal Ethic Committee of the Center of 
Molecular Immunology, in accordance with its animal care and 
use guidelines.
In a first series of experiments, adolescent (6-week olds) (30), 
young adult (16-week olds), middle-aged/old (56- to 76-week 
olds) male, and middle-aged (35-week olds) female apoE−/− 
mice (31) fed a chow diet received four s.c. injections of 50 μg 
of chP3R99-LALA mAb at weekly intervals, followed by two 
additional biweekly injections. Blood samples were drawn and 
sera were obtained before treatment and 1 week after the fourth, 
fifth, and sixth injection of the mAb.
In a second experimental design, age-matched male and 
female apoE−/− mice were fed with a HFHC diet containing 20% 
(wt/wt) lard and 1% (wt/wt) cholesterol (Sigma-Aldrich) from 
6 weeks of age. Mice were treated with s.c. injections of either 
50 μg of chP3R99-LALA or hR3 mAb at 12, 13, 14, 15, 17, and 
19 weeks of age. In addition, middle-aged female apoE−/− mice 
fed a chow diet underwent the same immunization protocol, as 
shown in Figure S2A in Supplementary Material.
In a third series of experiments, 6-week-old male apoE−/− mice 
fed a chow diet were treated with four weekly s.c. injections of 50 
or 200 μg of chP3R99-LALA mAb. Blood samples were obtained 
at the beginning of the study and a week after the administration 
of the third and fourth injection.
In a fourth experimental protocol, male apoE−/− mice fed with 
the HFHC diet were treated with s.c. injections of 50 or 200 μg 
of chP3R99-LALA mAb or with 200 μg of isotype-matched mAb 
hR3, at 12, 13, 14, 15, 17, and 19 weeks of age.
Also, 1  week after the last immunization, the mice were 
anesthetized with ketamine hydrochloride (5  mg/kg i.m.) and 
euthanized with an overdose of sodium pentobarbital (90 mg/kg, 
i.v.) (Abbott Laboratories, Mexico City, Mexico). In the second 
and fourth experimental protocol, the vascular system was per-
fused with 0.9% NaCl solution at 4°C and then, whole aortas were 
isolated for morphometric analysis.
Morphometric analysis of aortic lesions
Aortas were opened longitudinally from the heart to the iliac 
arteries, and the lesions were stained with Oil-Red-O, as 
described previously (32). En face stained-aortas were digitized 
by light microscopy and analyzed using Adobe Photoshop CS3 
software (Adobe Systems Incorporated, San José, CA, USA) 
and expressed as the percentage of the total aortic surface area 
covered by lesions.
reactivity of sera against chimeric 
antibodies
Reactivity of immune sera against chimeric antibodies was deter-
mined by solid-phase ELISA as previously described (27). Briefly, 
96-well Maxisorp polystyrene plates (Nunc, Roskilde, Denmark) 
were coated with 10 μg/mL of chP3R99-LALA, ch1E10, or hR3 
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mAb and incubated overnight at 4°C. Diluted sera (1/1,000) were 
added and the plates were incubated for 1 h at 37°C. Peroxidase-
conjugated goat anti-mouse IgG secondary antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) was used 
to determine the reactivity associated with IgG fraction using 
0.4  mg/mL of ortho-phenylenediamine in citrate/phosphate 
buffer, pH 5 containing 0.2% of H2O2. Sera reactivity is expressed 
as OD values at 490 nm.
reactivity of sera against cs
The presence of antibodies against CS was assessed by solid-phase 
ELISA, as previously described (27). Maxisorp polystyrene ELISA 
plates (Nunc) were coated with 10 μg/mL of CS and incubated 
overnight at 4°C. Mice sera (1/400) was added to the plates and 
incubated for 1 h at room temperature. Peroxidase-conjugated goat 
anti-mouse IgG secondary antibody (Jackson ImmunoResearch 
Laboratories) was added and the plates incubated for 1 h at room 
temperature. Colorimetric reaction was developed using 0.4 mg/
mL of ortho-phenylenediamine in citrate/phosphate buffer, pH 5 
containing 0.2% of H2O2. Sera reactivity is expressed as OD values 
at 490 nm.
The pattern of IgG subclasses developed in immunized 
mice was determined using biotinylated goat anti-mouse 
IgG1, IgG2a, IgG2b, or IgG3 (BD Pharmingen, San Diego, CA, 
USA), followed by incubation with streptavidin-conjugated to 
alkaline phosphatase (Jackson ImmunoResearch Laboratories) 
for 30 min at 37°C. The reaction was developed using 1 mg/mL 
of para-nitrophenyl phosphate in diethanolamine buffer solu-
tion pH 9.
Antibody response induction was considered positive when 
hyperimmune serum OD was ≥0.2 and at least twofold the pre-
immune serum OD value. Assays were performed in triplicate 
for each sample and the coefficient of variation was <15% for all 
values.
statistical analysis
All data are represented as mean  ±  SEM. Statistical analysis 
was performed with the GraphPad Prism version 6.0 software 
(GraphPad Software Inc., San Diego, CA, USA). Comparisons 
between independent groups were performed using one-way 
ANOVA followed by Tukey post  hoc test or Student’s t-test as 
appropriate.
resUlTs
chP3r99-lala mab induced anti-cs 
autologous antibody response 
independently of age and gender in 
apoe−/− Mice Fed a chow Diet
To assess the effect of aging in the capacity of chP3R99-LALA 
mAb to induce an anti-CS antibody response, adolescent, young 
adult, and middle-aged/old, apoE−/− male mice received six s.c. 
injections of 50 μg of the mAb. The presence of anti-CS autolo-
gous antibodies was measured in pre- and hyperimmune serum 
samples through their binding to CS-coated ELISA microplates. 
IgG anti-CS levels were significantly higher in hyperimmune sera 
from all mice groups in comparison with those detected in the 
preimmune sera (Figures  1A–C, P <  0.0001). To evaluate the 
impact of gender in the induction of anti-CS antibody response by 
the administration of chP3R99-LALA mAb, middle-aged female 
apoE−/− mice were immunized with the same immunization 
schedule. Hyperimmune sera also displayed a stronger reactivity 
against CS compared with preimmune sera, as observed for males 
(Figure 1D, P < 0.0001). These autologous antibody responses 
reached a plateau in all groups after the mice received the fourth 
or fifth injection of chP3R99-LALA mAb (Figures 1A–D). No 
differences were found in anti-CS antibody levels irrespective 
of age and gender after the sixth immunization (Figure S1 in 
Supplementary Material).
chP3r99-lala mab had a similar 
antiatherosclerotic effect in apoe−/−  
Mice of Both genders
Next, we evaluated whether similar induced anti-CS antibody 
responses between male and female apoE−/− mice treated with 
chP3R99-LALA mAb would confer similar atheroprotection. The 
antiatherogenic effect of chP3R99-LALA mAb was assessed in 
apoE−/− mice of both gender fed a HFHC diet from 6 weeks of 
age, and injected s.c. with six doses (50 μg/dose) of chP3R99-
LALA mAb or isotype control mAb hR3, starting at 12-week olds 
according to the schedule shown in Figure 2A. At the end of the 
experiment, lipid accumulation in whole aortas was detected by 
en face staining with Oil-Red-O. Immunization with chP3R99-
LALA mAb similarly reduced the mean aortic lesion area by 
31% (P <  0.05) and 38% (P <  0.05) in male and female mice, 
respectively, compared with their respective isotype-matched 
control-treated group, even though the atherogenic diet was 
maintained during all the immunization protocol (Figures 2B,C). 
Interestingly, a similar decrease in the mean percent aortic lesion 
area (31%, P < 0.05) was observed in 35-week-old female apoE−/− 
mice with spontaneous development of atherosclerotic lesions, 
immunized with six doses of chP3R99-LALA mAb (50 μg/dose), 
in comparison with isotype-matched control treatment (Figure 
S2 in Supplementary Material).
The anti-cs antibody response induced 
in apoe−/− Mice Was Dependent on the 
Dose of chP3r99-lala mab administered
To evaluate the effect of increasing dose of chP3R99-LALA mAb 
on the anti-CS antibody response, 6-week-old male apoE−/− mice 
fed with chow diet received four injections of 50 or 200  μg 
of the antibody. IgG anti-CS response augmented with the 
number of administered injections in the 50 μg-treated group 
(Figure 3A, P < 0.0001), whereas the administration of 200 μg 
of chP3R99-LALA increased the antibody response in hyperim-
mune sera (P < 0.0001), reaching a plateau after mice received 
three injections (Figure 3B). The immunization with 200 μg of 
chP3R99-LALA induced higher anti-CS antibody response than 
50 μg when this response was measured in mice sera 7 days after 
the third (1.28 ± 0.15 vs. 0.55 ± 0.06, P < 0.0001) and the fourth 
(1.48 ± 0.13 vs. 0.74 ± 0.05, P < 0.0001) administration of the 
FigUre 1 | effect of age and gender on the induction of anti-chondroitin sulfate (cs) antibody response in apoe−/− mice immunized with chP3r99-
lala monoclonal antibody (mab). Mice fed a chow diet received four s.c. injections of 50 μg of chP3R99-LALA mAb at weekly intervals and two additional 
immunizations biweekly. Sera were obtained prior to the first antibody injection and after the fourth, fifth and sixth immunization of (a) adolescent (6-week olds, 
n = 5), (B) young adult (16-week olds, n = 5), (c) middle-aged/old (56- to 76-week olds, n = 3) male, and (D) middle-aged (35-week olds, n = 9) female apoE−/− 
mice. To measure the kinetics of the response against CS, sera from immunized mice (diluted 1:400) were added to enzyme-linked immunoadsorbent assay plates 
coated with 10 μg/mL of CS and the reaction was developed with peroxidase-conjugated goat anti-mouse IgG. The levels of anti-CS antibodies are expressed as 
optical density (OD) values. Results are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA followed by Tukey post hoc test.
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mAb. The anti-CS response induced exclusively antibodies of 
IgG1 subclass (data not shown).
The anti-idiotype (ab2) and anti-anti-
idiotype antibody (ab3) responses 
induced in apoe−/− Mice Were Dependent 
on the Dose of chP3r99-lala mab 
administered
Knowing that the immunization with chP3R99-LALA mAb 
(Ab1) is able to induce an anti-idiotype antibody cascade in 
apoE−/− mice (27), we evaluated whether the increase in the 
anti-CS antibody response detected in apoE−/− mice treated with 
200 μg of the mAb was associated with an increase of the anti-
idiotypic (Ab2) and anti-anti-idiotypic (Ab3) antibody responses. 
To evaluate the dose-dependence of the Ab2 response, serological 
IgG reactivities against chP3R99-LALA whole molecule and the 
isotype-matched-control mAb (hR3) were determined by ELISA. 
The injection of 50 μg (Figure 4A) and 200 μg (Figure 4B) gener-
ated a higher antibody immune response against chP3R99-LALA 
molecule than against the isotype-matched antibody control 
(P < 0.0001), showing the immunodominance of chP3R99-LALA 
idiotype. However, four administrations of 200 μg of the mAb 
induced not only a higher level of anti-chP3R99 IgG antibodies 
than 50 μg (2.41 ± 0.07 vs. 1.29 ± 0.12, P < 0.0001) but also a 
lower response against the isotype (0.20 ± 0.05 vs. 0.62 ± 0.08, 
P < 0.001).
In addition, we determined the presence of Ab3 antibodies 
in the sera of chP3R99-LALA-treated mice, measuring by ELISA 
their reactivity against an Ab2 mAb that binds chP3R99-LALA-
idiotype, named ch1E10. Although hyperimmune sera from 
apoE−/− mice immunized with either 50 or 200 μg of chP3R99-
LALA mAb reacted with ch1E10 mAb, only those sera from 
mice treated with four injections of the higher dose showed a 
significant specific binding to the Ab2 mAb in comparison with 
the reactivity against the isotype-matched antibody control hR3 
(Figures 4C,D, P < 0.05).
The antiatherogenic effect generated by 
chP3r99-lala mab immunization in 
apoe−/− Mice Was Dependent on the Dose
Finally, we tested the effect of different doses of chP3R99-LALA 
mAb on the atherosclerotic lesion progression in apoE−/− male 
mice fed HFHC diet from 6 to 20 weeks of age and treated with six 
injections of 50 or 200 μg of the antibody, starting the immuniza-
tions when animals were 12 weeks of age (Figure 5A). En face 
analysis of whole aortas showed that mean aortic lesion areas of 
FigUre 2 | effect of immunization with chP3r99-lala monoclonal antibody (mab) on atherosclerosis development in apoe−/− mice of both genders. 
(a) Experimental design: arrows represent immunization time points with 50 μg of chP3R99-LALA mAb or the isotype-matched control hR3 mAb. Blue and red bars 
indicate treatment and high-fat high-cholesterol diet period, respectively. (B) Representative en face Oil-Red-O stained aortas from each experimental group.  
(c) Mean percentage of aortic lesion areas in male and female apoE−/− mice treated with chP3R99-LALA (n = 11 or 8) or hR3 (n = 8 or 4). Results are mean ± SEM. 
*P < 0.05, Student’s t-test.
FigUre 3 | antibody response to chondroitin sulfate (cs) in the sera 
of apoe−/− mice immunized with different doses of chP3r99-lala 
monoclonal antibody (mab). A 6-week-old mice fed with chow diet 
received four weekly s.c. injections of (a) 50 μg (n = 9) or (B) 200 μg (n = 10) 
of chP3R99-LALA mAb. Sera obtained before starting immunizations and 
1 week after the third and fourth antibody injection (diluted 1:400) were 
added to enzyme-linked immunoadsorbent assay plates coated with 10 μg/
mL of CS and the reaction was developed with peroxidase-conjugated goat 
anti-mouse IgG. The levels of IgG are expressed as OD values. Results are 
mean ± SEM. *P < 0.05, ***P < 0.001, one-way ANOVA followed by Tukey 
post hoc test.
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50 and 200 μg chP3R99-LALA-treated mice were reduced by 40% 
(P < 0.0001) and 60% (P < 0.0001) compared with the isotype-
matched control mAb-treated group, respectively (Figures 5B,C).
DiscUssiOn
Aging is one of the most important non-modifiable risk factor 
for the development of atherosclerosis in human and mice (15, 
33). On the other hand, aged humans and mice display impaired 
T and B cell responses (24–31). In particular, antibody responses 
could be reduced in magnitude and the antibodies could be less 
protective compared with those induced in young adults (34–40). 
Therefore, any therapeutic approach directed to efficiently acti-
vate immune responses in aging diseases, such as atherosclerosis, 
must take into account this fact.
In addition to the known induction of autologous anti-GAG 
antibodies in adolescent and young adult apoE−/− male mice 
immunized with chP3R99-LALA mAb (27, 41), we extend 
our previous findings by showing that in middle-aged and old 
apoE−/− mice, immunization with chP3R99-LALA mAb induced 
anti-CS antibody responses of similar levels and kinetics as in 
young animals, irrespective of the gender. Indeed, a similar 
reduction in the percentage of aortic lesion area in 12-week-old 
male and female apoE−/− mice fed a HFHC diet, when compared 
to their respective isotype-matched control antibody-treated 
groups, showed the capacity of chP3R99-LALA mAb to induce 
atheroprotection in both genders. In addition, the mean aortic 
area with spontaneous lesions was decreased in 35-week-old 
FigUre 5 | antiatherosclerotic effect induced by chP3r99-lala monoclonal antibody (mab) immunization at different doses in apoe−/− mice.  
(a) Experimental design: arrows represent immunization points according to the experimental procedure with 50 μg of chP3R99-LALA mAb (n = 11), 200 μg of 
chP3R99-LALA mAb (n = 14), or 200 μg of hR3 mAb (n = 8). (B) Representative en face Oil-Red-O-stained aortas from the different groups. (c) Mean percentage 
of aortic lesion area in apoE−/− mice treated with 50 or 200 μg of chP3R99-LALA or hR3. Results are mean ± SEM. *P < 0.05, ***P < 0.001, one-way ANOVA 
followed by Tukey post hoc test.
FigUre 4 | anti-idiotype (a,B) and anti-anti-idiotype (c,D) antibody 
responses induced in apoe−/− mice by immunization with doses of 
50 μg (a,c) and 200 μg (B,D) of chP3r99-lala monoclonal antibody 
(mab). The anti-idiotype (a,B) and anti-anti-idiotype (c,D) antibody 
responses were measured by enzyme-linked immunoadsorbent assay, 
adding mice sera (diluted 1:1,000) to chP3R99-LALA mAb- or ch1E10 Ab2 
mAb-coated plates, respectively (white bars). hR3 mAb-coated plates were 
used to measure the anti-isotype response (black bars). The reaction was 
developed with peroxidase-conjugated goat anti-mouse IgG. Sera were 
obtained before the first antibody injection and 1 week after the third and 
fourth immunization. The serological antibody responses are expressed as 
OD values. Results are mean ± SEM. *P < 0.05, ***P < 0.001, Student’s 
t-test when the levels of anti-chP3R99-LALA or anti-ch1E10 mAb serological 
antibody responses were compared with those against hR3 mAb.
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findings of the induction of the anti-CS response and may 
suggest that the antiatherosclerotic capacity of chP3R99-LALA 
mAb is not influenced by age, at least across the age range 
evaluated.
In previous studies (27, 41), anti-GAG antibody response and 
antiatherogenic effect of 50 μg of chP3R99-LALA was tested. To 
address dose-dependency, we determined the anti-CS antibody 
response induced by a fourfold higher dose of chP3R99-LALA 
mAb. The results showed that the response plateaued earlier and 
the levels of serological anti-CS antibodies were significantly 
higher than those induced with 50 μg of the mAb. Improvement 
of anti-CS antibody response with 200  μg of chP3R99-LALA 
was associated with the generation of higher levels of Ab2 
and Ab3 responses in apoE−/− mice treated with this dose. A 
surprising result was that not only a higher antibody response 
against chP3R99-LALA idiotype was observed with 200 μg but 
also a significantly lower one was found against the isotype in 
comparison with 50 μg-immunized animals. One explanation for 
this finding could be that, although the human constant region 
of this chimeric antibody constitutes 70% of the immunoglobulin 
molecule, the murine idiotype of this mAb is more immunogenic 
and thus is immunodominant in the induction of the humoral 
response against chP3R99-LALA in mice (27). Accordingly, 
when the immune system of apoE−/− mice was exposed to a 
higher dose of chP3R99-LALA molecules, an increased number 
of B-lymphocytes may be triggered to produce anti-idiotype 
antibodies and, in turn, less would produce antibodies reacting 
with the isotype. Interestingly, the IgG antibody response induced 
by chP3R99-LALA in immunized mice was restricted to the IgG1 
subclass, which is associated with a Th2-like, non-inflammatory 
humoral response (42).
The demonstration of anti-GAG antibodies induced in 
chP3R99-LALA-immunized apoE−/− mice was related to the 
activation of an anti-idiotype antibody cascade that generates 
female apoE−/− mice immunized with chP3R99-LALA com-
pared to control treatment, in a similar fashion to young male 
and female apoE−/− mice. This observation is in line with our 
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